Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 5/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coralgil SCHEMBL26128795 | 1.00 | EBP (0.61) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| Coralgil SCHEMBL29989837 | 0.98 | EBP (0.59) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| Coralgil SCHEMBL1649422 | 0.97 | EBP (0.58) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL9706125 | 0.85 | EBP (0.72) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL12015816 | 0.84 | KDM4E (0.67) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL2425061 | 0.81 | EBP (0.55) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL2426949 | 0.81 | EBP (0.55) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL9827594 | 0.81 | EBP (0.59) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL3420518 | 0.78 | EBP (0.64) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL864035 | 0.78 | SLC2A1 (0.56) | EBPSIGMAR1CYP2D6HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| EP-3072526-A1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | Oncomed Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2488204-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2016-04-06 | — | — | EP | claimed |
| US-20150118232-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2015-04-30 | — | — | US | claimed |
| US-7354581-B2 | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent | REGENERON PHARMACEUTICALS, INC. (US) | 2008-04-08 | — | — | US | claimed |
| EP-1853298-A2 | THERAPEUTIC COMBINATION OF A VEGF ANTAGONIST (VEGF TRAP) AND AN ANTI-HYPERTENSIVE AGENT | REGENERON PHARMACEUTICALS, INC. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2007098390-A2 | METHOD FOR TREATING RESISTANT HYPERTENSION | GILEAD COLORADO, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| WO-2006086544-A2 | THERAPEUTIC COMBINATION OF A VEGF ANTAGONIST (VEGF TRAP) AND AN ANTI-HYPERTENSIVE AGENT | REGENERON PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060183684-A1 | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent | REGENERON PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20240374559-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-11-14 | — | — | US | disclosed |
| US-20240293358-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | Universite de Bordeaux (FR) | 2024-09-05 | — | — | US | disclosed |
| EP-4333827-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | UNIVERSITE DE BORDEAUX (FR) | 2024-03-13 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0449463-B1 | Method and composition for iontophoresis | BECTON DICKINSON CO (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5302172-A | Method and composition for iontophoresis | NORTH CAROLINA STATE UNIVERSITY (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0449463-A2 | Method and composition for iontophoresis | Becton, Dickinson and Company (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293358-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | PPARD, PPARA, PPARG | EBP 785/4885SIGMAR1 2201/4885CYP2D6 2553/4885 |
| US-20240374559-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | PPARD, PPARA, PPARG | EBP 785/4885SIGMAR1 2201/4885CYP2D6 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.